FDA approves glucarpidase injection for treatment of toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function

ASCO SIGN IN

Manage Email Subscriptions

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

ASCO Membership Directory

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Practice & Guidelines

Practice Management & Reimbursement

FDA Drug Alerts

FDA approves glucarpidase injection for treatment of toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function

On January 17, 2012, the U. S. Food and Drug Administration approved glucarpidase injection (Voraxaze®, BTG International Inc.) for the treatment of toxic plasma methotrexate concentrations (> 1 µmol/L) in patients with delayed methotrexate clearance due to impaired renal function.*

The approval was based on the pharmacodynamic endpoint of a rapid and sustained clinically important reduction (RSCIR) in plasma methotrexate concentration, defined as an attainment of plasma methotrexate concentration =1 µmol/L within 15 minutes following glucarpidase administration and sustained for up to 8 days.

Efficacy was established in 22 patients with delayed methotrexate clearance (more than 2 standard deviations above the average indicated on standard nomograms) secondary to renal dysfunction. The efficacy assessment was limited to patients having pre- and post-treatment plasma samples collected and handled according to a validated procedure to yield reliable methotrexate measurements by HPLC.

All patients received glucarpidase, 50 Units/kg, as an intravenous injection over 5 minutes. Patients with pre-glucarpidase methotrexate concentrations >100 µmol/ L were to receive a second dose of glucarpidase 48 hours after the initial dose. All patients received vigorous intravenous hydration, urinary alkalinization, and leucovorin rescue.

Ten of the 22 patients met the criteria for RCSIR [45% (95% CI: 27, 65)]. Efficacy was dependent on pre-treatment methotrexate levels. Ten of 13 patients (77%) who had baseline methotrexate levels between 1-50 µmol/L achieved an RSCIR, however, none of the 9 patients with pre-glucarpidase methotrexate concentrations > 50 µmol/L attained this endpoint. All evaluable patients exhibited more than 95% reduction in methotrexate concentration from pre-treatment baseline levels that was maintained for up to 8 days following glucarpidase therapy.

Safety data were evaluated in 290 patients treated in two single-arm, open-label, multicenter trials. These trials enrolled patients who had markedly delayed methotrexate clearance secondary to renal dysfunction. The median age was 17 years (1 month to 85 years), 64% were male, 32% had osteogenic sarcoma or sarcoma and 63% had leukemia or lymphoma. The most common adverse reactions (incidence >1%) were paraesthesias, flushing, nausea and/or vomiting, hypotension and headache.

Healthcare providers should note that:

Methotrexate concentrations within 48 hours following glucarpidase administration can only be reliably measured by a chromatographic method due to interference from metabolites [4-deoxy-4-amino-N10-methylpteroic acid (DAMPA)]. Measurement of methotrexate concentrations within 48 hours of glucarpidase administration using immunoassays can overestimate the methotrexate concentration.
Leucovorin should not be administered within 2 hours before or after a glucarpidase dose because leucovorin is a substrate for glucarpidase.

The recommended dose and schedule for glucarpidase is a as a single intravenous injection of 50 Units/kg.

* Limitation of Use: Glucarpidase is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Full prescribing information, including clinical trial information, safety, dosing, drug-drug interactions and contraindications is available on the FDA website.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088).